DC-NPRL2

DC-NPRL2 is an experimental nanoparticle-mediated gene therapy designed to restore the expression of the NPRL2 (Nitrogen permease regulator-like 2) tumor suppressor gene in cancer cells. The formulation utilizes DOTAP:cholesterol (DC) cationic liposomes to encapsulate and deliver the NPRL2 plasmid DNA systemically. NPRL2 is a critical component of the GATOR1 complex, which acts as a negative regulator of the mechanistic target of rapamycin complex 1 (mTORC1) pathway. Loss of NPRL2, frequently observed in non-small cell lung cancer (NSCLC) due to deletions in the 3p21.3 chromosomal region, leads to constitutive mTORC1 activation and resistance to apoptosis. By restoring NPRL2 function, DC-NPRL2 inhibits tumor cell proliferation, induces apoptosis, and enhances sensitivity to DNA-damaging agents like cisplatin. Developed primarily at the MD Anderson Cancer Center, this therapeutic candidate targets thoracic malignancies where NPRL2 expression is deficient.

Other names

DOTAP:Cholesterol-NPRL2NPRL2 gene therapyNPRL-2 gene therapyNPRL 2 gene therapyNPRL2 nanoparticleNPRL-2 nanoparticleNPRL 2 nanoparticle